Glioblastoma Companies
Glioblastoma multiforme (GBM) is an aggressive type of brain cancer, and companies in this space are primarily focused on developing innovative treatments, therapies, and technologies to address this challenging condition.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Glioblastoma Companies Update
-
October 2023: A investigator-initiated study, supported by the Ben & Catherine Ivy Foundation and Barrow Neurological Foundation, has effectively combined AstraZeneca-provided radiation therapy with the Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD1390 in the treatment of recurrent glioblastoma. The institute released preliminary findings from a phase 0/1 clinical trial of AZD1390 in combination with radiation therapy for recurrent glioblastoma. The study provided novel human evidence that AZD1390 could potentially function as a potent radiosensitizer in glioblastoma patients. It appears that tissue selectivity and blood-brain barrier penetration were the primary obstacles, but as in this study, contemporary approaches continue to attempt to overcome these challenges.
-
June 2023: Chimeric Therapeutics initiated a new Phase IB clinical trial for CHM 1101 (CLXT CAR T) cell therapy, which is designed to treat glioblastoma multiforme patients who have recurrent or progressive disease. The safety and efficacy of CHM 1101 in patients with the most lethal form of primary brain cancer will be assessed in this study. The recommended Phase II dose is determined by the two-part Phase IB study, which consists of Part A and Part B. Three to six patients will be enrolled in Part A of the study while the City of Hope Cancer Centre determines the optimal dose. Part B will include an additional twelve to twenty-six patients. Late this year, Chimeric will also assess the activity and safety of the CHM 1101 clinical program. The utilization of multiple clinical trial sites for recruitment in this multi-center trial will expedite the development of CHM 1101. Furthermore, should the clinical results support this, it will also position us to accelerate the subsequent phase of development.
List of Glioblastoma Key companies in the market
- F. Hoffmann-La Roche Ltd (Switzerland)
- Arbor Pharmaceuticals, LLC (US)
- Merck & Co., Inc. (US)
- Sun Pharmaceutical Industries Ltd (India)
- Amgen Inc. (US)
- Teva Pharmaceutical Industries Ltd (Israel)
Glioblastoma Market Highlights:
Glioblastoma Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
